Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson's disease

Movement Disorders

Volumn 23, Issue 3, 2008, Pages 359-365

  Kulkarni, Amit S ^a   Balkrishnan, Rajesh ^a   Anderson, Roger T ^b   Edin, Heather M ^c   Kirsch, Jeff ^d   Stacy, Mark A ^e  

^a OHIO STATE UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Elderly; Medications; Parkinson's disease; Prevalence

Indexed keywords

ANTIPARKINSON AGENT;

AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOCTOR PATIENT RELATION; HEALTH MAINTENANCE ORGANIZATION; HEALTH PERSONNEL ATTITUDE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; UNITED STATES; AGE; ECONOMICS; FEMALE; GERIATRICS; HOSPITALIZATION; MALE; STATISTICS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; FEMALE; GERIATRICS; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; LONGITUDINAL STUDIES; MALE; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 43049180404     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21831     Document Type: Article

References (31)

1. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:1015-1022.
2. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. (erratum in Am J Epidemiol 1996;143: 528). Am J Epidemiol 1995;142:820-827.
3. Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. Mov Disord 2005;20:1397-1404.
4. Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. Mov Disord 2005;20:1449-1454.
5. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005;20:1502-1507.
6. Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson's disease. Mov Disord 2004;19:513-517.
7. Nausieda PA, Pfeiffer RF, Tagliati M, Kastenholz KV, DeRoche C, Slevin JT. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease (erratum in Clin Ther 2005;25:360). Clin Ther 2005;27:58-63.
8. Leoni O, Martignoni E, Cosentino M, et al. Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol Drug Saf 2002;11:149-157.
9. Ward C. Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study. J Neurosci Nurs 2005;37:160-162.
10. Mizuno Y, Takubo H, Mizuta E, Kuno S. Malignant syndrome in Parkinson's disease: concept and review of the literature. Parkinsonism Relat Disord 2003;9 (Suppl 1):S3-S9.
11. Pearce RK, Banerji T, Jenner P, et al. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998;13:234-241.
12. Rascol O, Brooks DJ, Korczyn AD, et al. A 5-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.
13. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
14. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37:846-857.
15. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988;26:814-823.
16. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-457.
17. Schwartz D, Wang M, Zeitz L, Goss ME. Medication errors made by the elderly, chronically ill patients. Am J Public Health 1962; 52:2018-2029.
18. Dunbar-Jacob J, Erlen JA, Schlenk EA, Ryan CM, Sereika SM, Doswell WM. Adherence in chronic disease. Annu Rev Nurs Res 2000;18:48-90.
19. Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. J Clin Epidemiol 2001;54 (Suppl 1):S57-S60.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
21. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
22. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-1224.
23. O'Brien MK, Petrie K, Raeburn J. Adherence to medication regimens: updating a complex medical issue. Med Care Rev 1992;49: 435-454.
24. Cramer JA. Effect of partial compliance on cardiovascular medication effectiveness. Heart 2002;88:203-206.
25. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001;26:331-342.
26. DiMatteo MR. Enhancing patient adherence to medical recommendations. JAMA 1994;271:79-83.
27. Conrad P. The meaning of medications: another look at compliance. Soc Sci Med 1985;20:29-37.
28. Roberson MHB. The meaning of compliance: patient perspective. Qual Health Res 1992;2:7-22.
29. Jani AA, Stewart A, Nolen RD, Tavel L. Medication adherence and patient education. In: Beal J, Orrick JJ, Alfonso K, Rathore M, editors. HIV/ AIDS primary care guide. Florida: Florida/Caribbean AIDS Education Training Center, University of South Florida; 2006. p 165-175.
30. Tseng C, Brook RH, Keeler E, Steers WN, Mangione CM. Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA 2004; 292:952-960.
31. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med 2006;354:2349-2359.